Dr Anne Beal has joined the board of GlaxoSmithKline as a non-executive director.

She has been appointed to the GSK corporate responsibility committee and will succeed Lynn Elsenhans as chair of the committee following the 2022 AGM. Elsenhans has agreed to remain on the board for a further year to facilitate a smooth transition.

Beal is founder and CEO of AbsoluteJOI Skincare and a member of the board of AcademyHealth. She spent six years at Harvard Medical School and Massachusetts General Hospital, where she was an instructor in paediatrics, and has also held leadership roles at the Commonwealth Fund and the Aetna Foundation.

Beal is a recognised health policy expert in the development of global and national programmes for improving healthcare access for all patient groups and in ensuring the voice of patients is reflected in research programmes.

Sir Jonathan Symonds, chair of GSK, said: “I am delighted to welcome Anne to GSK. Acting responsibly is an integral part of how successful modern businesses deliver for a wide range of stakeholders including investors. That’s why the work of the corporate responsibility committee is critical to the success of GSK. Anne’s expertise and experience will be a valuable addition to GSK and to the leadership of the committee.”